BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Treprostinil (Remodulin) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Treprostinil (Remodulin)\, from ClinicalT
 rials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06317805-11040@assetmemo.bio
DTSTAMP:20261121T004115Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Treprostinil (Remodulin): Phase 4 readout est. (NCT06317805)
DESCRIPTION:Treprostinil (Remodulin)\, phase 4\, Pulmonary Arterial Hyperte
 nsion.\nStudy: Initial Triple Therapy Including Parenteral Treprostinil vs
  Initial Double Oral Therapy in PAH Group I Patients\nEstimated primary co
 mpletion: June 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 treprostinil-remodulin#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06317805
URL:https://assetmemo.bio/drug/treprostinil-remodulin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04005469-11040@assetmemo.bio
DTSTAMP:20261121T004115Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Treprostinil (Remodulin): Phase 1/2 readout est. (NCT04005469)
DESCRIPTION:Treprostinil (Remodulin)\, phase 1/2.\nStudy: Safety and Effica
 cy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury D
 uring Kidney Transplantation\nEstimated primary completion: 30 June 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/treprostinil-remoduli
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04
 005469
URL:https://assetmemo.bio/drug/treprostinil-remodulin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06350032-11040@assetmemo.bio
DTSTAMP:20261121T004115Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Treprostinil (Remodulin): Phase 3 readout est. (NCT06350032)
DESCRIPTION:Treprostinil (Remodulin)\, phase 3\, Pulmonary Arterial Hyperte
 nsion.\nStudy: Investigational Trial to Evaluate Safety and Tolerability o
 f Treprostinil in Children Diagnosed With PAH\nEstimated primary completio
 n: November 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tre
 prostinil-remodulin#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06350032
URL:https://assetmemo.bio/drug/treprostinil-remodulin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
